These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8886078)

  • 21. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The chimpanzee as a model of human benign prostatic hyperplasia.
    Steiner MS; Couch RC; Raghow S; Stauffer D
    J Urol; 1999 Oct; 162(4):1454-61. PubMed ID: 10492237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relation between the prostatic tissue components and natural history, estrogen receptor].
    Matsuda T; Abe H; Suda K
    Rinsho Byori; 2003 Dec; 51(12):1180-3. PubMed ID: 14743740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental research on spontaneous benign prostatic hyperplasia in old dogs].
    Cai RF; Cui YG; Hua LX; Jia Y; Ma DZ; Wang XH
    Zhonghua Nan Ke Xue; 2003 Dec; 9(9):651-3, 657. PubMed ID: 14727348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.
    Crispo A; Talamini R; Gallus S; Negri E; Gallo A; Bosetti C; La Vecchia C; Dal Maso L; Montella M
    Urology; 2004 Oct; 64(4):717-22. PubMed ID: 15491708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
    Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
    J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Volumetric density of elastic and reticular fibers in transition zone of controls and patients with benign prostatic hyperplasia.
    Costa WS; de Carvalho AM; Babinski MA; Chagas MA; Sampaio FJ
    Urology; 2004 Oct; 64(4):693-7. PubMed ID: 15491703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Epidemiology and natural course of benign prostatic hyperplasia].
    Blom JH; Schröder FH
    Urologe A; 1992 May; 31(3):129-34. PubMed ID: 1377429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
    Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
    Byun SS; Jeong H; Jo MK; Lee E
    Urology; 2005 Sep; 66(3):593-6. PubMed ID: 16140084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
    Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased expression of NKX3.1 in benign prostatic hyperplasia.
    Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
    Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in prostatic stromal composition and benign prostatic hyperplasia].
    Shen W; Mao XM; Lü J; Yao HQ; Deng ZX; Zhao YB; Liu J; Hua W; Wang BQ; Hu WL
    Zhonghua Nan Ke Xue; 2011 Aug; 17(8):703-6. PubMed ID: 21898992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocytic vasculitis of the prostate transition zone.
    Lopez-Beltran A; Vidal A; Montironi R; Kirkali Z; Muñoz E; Blanca A; Cheng L
    BJU Int; 2012 Dec; 110(11):1775-80. PubMed ID: 22462607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules].
    Manzarbeitia F; Vela Navarrete R; Fernández-Aceñero MJ
    Actas Urol Esp; 2010 Jun; 34(6):549-54. PubMed ID: 20510119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The origin and development of benign prostatic hyperplasia. An age-dependent process.
    Oesterling JE
    J Androl; 1991; 12(6):348-55. PubMed ID: 1722790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benign prostatic hyperplasia: a review of its histogenesis and natural history.
    Oesterling JE
    Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.